Disease activity and treatment efficacy using patient-level Psoriasis Area and Severity Index scores from tildrakizumab phase 3 clinical trials.
2020
Background: It is unclear whether primary efficacy outcomes in plaque psoriasis clinical trials represent residual disease during treatment.Objectives: To evaluate supplementing dichotomous efficac...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
30
References
6
Citations
NaN
KQI